Androgen News and Research

RSS

Early metformin treatment may prevent adolescent polycystic ovary syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that early, prolonged treatment with the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome (PCOS) in adolescence.

30 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI.

22 Jun 2011

Smoking may increase risk of death from prostate cancer

Men who are diagnosed with prostate cancer and who are also smokers have an associated increased risk of all-cause, cardiovascular and prostate cancer-specific death, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

Cancer is crafty. When one avenue driving its growth is blocked by drugs targeting that path, the malignancy often creates a detour, finding an alternative route to get around the roadblock.

16 Jun 2011

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa).

9 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.

6 Jun 2011

Weight loss after bariatric surgery may reverse low testosterone, sexual dysfunction in obese men

Low testosterone levels and symptoms of male sexual dysfunction due to obesity may be reversible with weight loss after bariatric surgery, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

New targeted therapy may halt tumor growth in men with advanced prostate cancer

A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Androgen News and Research

Early metformin treatment may prevent adolescent polycystic ovary syndrome

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Smoking may increase risk of death from prostate cancer

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Weight loss after bariatric surgery may reverse low testosterone, sexual dysfunction in obese men

New targeted therapy may halt tumor growth in men with advanced prostate cancer

PCF funds 14 new Creativity Awards for advanced prostate cancer research

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Stopping prostate cancer cells from 'bulking up' with nutrients blocks spread of disease

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Obese men may face high risk of prostate cancer progression

GTx reports net loss of $2.6 million for first quarter 2011

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News